Blocking the FGFR or MAPK pathways with pharmacological inhibitors compromises the growth of these PCas both in vitro and in vivo, indicating that FGFR/MAPK contributes to escaping from the AR regulation and that the FGFR/MAPK blockade can be a new strategy to treat metastatic PCa with an AR-null phenotype (Bluemn et al., 2017). This evidence concerns the gene AR and posterior cortical atrophy.